Answer
Rifampicin, a strong CYP3A inducer, markedly reduces bosutinib exposure, and increasing the bosutinib dose is unlikely to sufficiently compensate for this loss.
Sources for this answer
- Bosutinib 100 mg film-coated tabletsDr. Reddy's Laboratories (UK) Ltd · emc · SmPC §4.5 Interaction with other medicinal products · Version 2Document updated
Sources checked